Shattuck Labs(US:STTK)2026-03-05 11:23Financial Performance - Shattuck Labs reported a net loss of $12.6 million for Q4 2025, or $0.12 per share, compared to a net loss of $18.7 million, or $0.37 per share, in Q4 2024[7][8]. - For the full year 2025, the net loss was $48.8 million, or $0.70 per share, down from $75.4 million, or $1.49 per share, in 2024[8]. - The net loss for the year ended December 31, 2025, was $48,809, compared to a net loss of $75,410 in 2024, showing an improvement of 35%[18]. - Basic and diluted net loss per share for the year ended December 31, 2025, was $0.70, compared to $1.49 in 2024, representing a reduction of 53%[18]. - Comprehensive loss for the year ended December 31, 2025, was $48,805, compared to $75,412 in 2024, marking a decrease of 35%[18]. Revenue and Income - Total revenue for the year ended December 31, 2025, was $1,000, compared to $5,721 in 2024, indicating a significant decline[18]. - Interest income for the year ended December 31, 2025, was $2,703, compared to $5,174 in 2024, reflecting a decline of about 48%[18]. - Other income for the year ended December 31, 2025, totaled $2,699, down from $5,157 in 2024, a decrease of approximately 48%[18]. Expenses - Research and Development (R&D) expenses decreased to $9.1 million in Q4 2025 from $15.4 million in Q4 2024, and for the full year, R&D expenses were $35.3 million, down from $67.2 million in 2024[7][8]. - General and Administrative (G&A) expenses for Q4 2025 were $4.3 million, slightly up from $4.2 million in Q4 2024, while full-year G&A expenses decreased to $17.2 million from $19.1 million[7][8]. - Total operating expenses for the year ended December 31, 2025, were $52,508, down from $86,288 in 2024, a decrease of approximately 39%[18]. - Research and development expenses for the three months ended December 31, 2025, were $9,057, down from $15,395 in 2024, reflecting a decrease of approximately 41%[18]. - General and administrative expenses for the three months ended December 31, 2025, were $4,316, slightly up from $4,246 in 2024, showing a marginal increase of 1.6%[18]. Cash Position - Cash and cash equivalents and short-term investments as of December 31, 2025, were approximately $78.1 million, an increase from $73.0 million as of December 31, 2024[9]. - As of February 28, 2026, cash and cash equivalents and short-term investments were approximately $94.5 million, including the recent stock sale proceeds[9]. - Following a common stock sale in Q1 2026, Shattuck expects its cash runway to extend into 2029, assuming full exercise of outstanding warrants[9]. Clinical Development - The Phase 1 clinical trial of SL-325 is nearing completion, with data expected in Q2 2026, and a Phase 2 trial in Crohn's disease anticipated to start in Q3 2026[2][4]. - Shattuck's lead bispecific antibody has entered IND-enabling activities, with target disclosures and preclinical data expected in the first half of 2026[4]. Management Changes - The company appointed Michael Choi, M.D., as Vice President of Clinical Development in November 2025, enhancing its management team[3]. Shareholder Information - The weighted-average shares outstanding for basic and diluted shares increased to 69,584,937 in 2025 from 50,758,290 in 2024, indicating a growth of approximately 37%[18].